Medical cannabis and attention-deficit hyperactivity disorder

Abstract

Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental condition that is estimated to affect 5% of children and adolescents worldwide. The core manifestations of ADHD include impulsivity, inattentiveness and hyperactivity, with there being a high proportion of individuals also experiencing other psychiatric co-morbidities. Currently available treatments for ADHD are limited by the low adherence rates related to adverse events. However, it has been suggested that cannabis-based medicinal products (CBMPs) may be effective in the treatment of ADHD, as evidence has shown how cannabis can lead to improvements in symptoms of hyperactivity and impulsivity. However, there is still limited published data supporting its use and further randomised controlled trials are required to help establish the efficacy, safety and exact role of CBMPs for the treatment of ADHD. ADHD patients can be assessed for receiving potential treatment with CBMPs by specialist clinics, such as Sapphire Medical Clinics, in instances where they have failed to respond to their treatment.